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224 Genotype–phenotype correlation of pancreatic function in
children with cystic ﬁbrosis
S. Sciuca1, O. Turcu1, G. Posselt2, B. Tu¨mmler3. 1State Medical and
Pharmaceutical University, Pediatrics, Chisinau, Moldova; 2University Hospital
of Johann Wolfgang Goethe, Pediatrics, Frankfurt/Main, Germany; 3Medical
University of Hannover, Hannover, Germany
Objective: To assess the level of fecal elastase-1 (FE-1) in relation to CFTR gene
mutations in patients with cystic ﬁbrosis (CF).
Materials and Methods: This study included 49 patients (23 boys) with CF, mean
age 8.43±0.99 years. CF was established on the basis of a positive sweat test
(Macroduct, Wescor USA) and the results of molecular genetic analysis. Genetic
diagnosis was realized for 36 CFTR mutations in genetic laboratories from Germany
and France. To detect pancreatic insufﬁciency (PI) was deﬁned FE-1 (ScheBo
Biotech, Germany). The values of FE-1 in the range 0–100mg/g, are characteristic
for severe exocrine PI, 100–200mg/g for moderate exocrine PI, and >200mg/g for
pancreatic sufﬁciency.
Results: F508del mutation was revealed in 73.33% cases (40.0% − homozygotes),
known genotype with other mutations was found in 18.26% cases. Low values of
FE-1 (7.89±3.70mg/g) conﬁrmed exocrine PI in 81.64% patients with CF. PI with
FE-1 of 2.90±0.78mg/g was conﬁrmed in 100% children with homozygous state of
F508del mutation. F508del mutation in heterozygous state caused decreased levels
of FE-1 (33.69±19.34mg/g). Only 5.88% patients with CF F508del heterozygous
were pancreatic sufﬁcient and other 11.7% cases were moderate PI. Non-F508del
CFTR mutations determined FE-1 levels of 218.64±64.87mg/g, with PI in 57.89%
patients.
Conclusion: The F508del mutations in homozygous state were associated with
severe pancreatic exocrine insufﬁciency in all patients. Heterozygous state of
mutation F508del requires association with another mutation and in most cases led
to pancreatic enzyme deﬁciency. Non-F508del CFTR mutations are not obligatory
associated with PI.
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Objectives: Pancreatic insufﬁciency (PI) occurs in typical CF phenotype when
patients carry two severe mutations on both alleles. When at least one mutation
is mild, pancreatic function is preserved and pancreatitis can occur. Our aim is
to conﬁrm in small number of CF patients whether the risk of pancreatitis could
be predicted by PIP (pancreatic insufﬁciency prevalence) score, according to the
Canadian Consortium for CF Genetic Studies (CCCFGS).
Methods: We examined 164 CF patients [113 PI and 51 pancreatic sufﬁcient
(PS)] with identiﬁed mutations on both alleles from the CF Regional Centre of
Naples. 9/164 patients showed at least one episode of pancreatitis (PANC). We
classiﬁed their mutations in severe and mild according to CF Mutation Database
(www.genet.sickkids.on.ca). PIP score was calculated as PI/ PI+PS patients carrying
the same mutation when in homozygous or in heterozygous with a severe one. We
applied the PIP score on each CF patient to determine their risk of pancreatitis,
using the lowest PIP score among the two identiﬁed mutations. According to the
cut-off deﬁned by CCCFGS, we divided CF genotype of our patients into mild
(PIP 0.25) and severe-moderate (PIP> 0.25). Patients with PANC and without
PANC showed a PIP score 0.25 5/9 (56%) and 36/155 (23%) respectively.
Conclusions: The percentage of patients with PIP score 0.25 was higher in
patients with PANC rather than in patients without PANC; the difference between
the two groups was statistically signiﬁcant (p< 0.05). As CFTR genotype seems to
be pivotal in the development of pancreatitis, the PIP score could be a prognostic
tool concerning the risk of pancreatitis, as previously suggested.
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Intestinal inﬂammation is present, in varying degrees, in cystic ﬁbrosis (CF).
The cause of inﬂammation is unclear but likely multi-factorial. The primary aim
was to deﬁne the stool calprotectin and S100A12 levels as markers for intestinal
inﬂammation in CF. The secondary aim was to deﬁne the relationship between
intestinal inﬂammation and pancreatic enzyme therapy (PERT).
Methods: Stools were collected in children with CF for calprotectin and S100A12
measurement. Comparisons were made to levels in healthy children (HC) and
children with active inﬂammatory bowel disease (IBD). Pancreatic function status
(sufﬁcient [PS] or insufﬁcient [PI]) and PERT dose were determined.
Results: 39 CF patients (median [range] yrs: 3.5 [4−18]), 31 IBD patients (3.3 yrs
[2.4−16]) and 30 HC (3.6 yrs [2.2–15.5]) were recruited. CF patients had sig-
niﬁcantly higher stool calprotectin levels compared with HC (median = 71.9 vs.
30.5mg/kg; p= 0.005), but lower than in IBD (median = 1265mg/kg; p< 0.0001).
Higher stool calprotectin levels were seen in those with PI (n = 35) than in those
with PS (n = 4) (median = 92.2 vs. 30.8mg/kg; p= 0.037). There was no signiﬁcant
difference in stool S100A12 levels between CF and HC (median = 0.4 vs. 1.2mg/kg;
p> 0.05) but stool S100A12 was signiﬁcantly raised in IBD (median = 55.2mg/kg;
p< 0.05) compared to both CF and HC. There was no correlation between stool
calprotectin levels and PERT dose (r = −0.08; p= 0.6).
Conclusion: Stool calprotectin but not S100A12 levels were raised in CF, especially
PI patients. There was no association between PERT dose and intestinal inﬂamma-
tion. These data may provide insight into the intestinal inﬂammatory pathways
involved in CF.
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Background and Objective: The small intestine is one of the main sites of cystic
ﬁbrosis (CF) manifestations and non-pancreatic intestinal factors are suggested to
contribute to fat malabsorption. Recent ﬁndings suggest that the small bowel mucosa
of CF patients frequently demonstrates inﬂammatory changes. Citrulline is a non-
protein amino acid synthesized in the small intestine and its plasma levels have
been proposed as a reliable intestinal marker in various conditions. The objective
of the present study was to investigate the value of plasma citrulline levels as a
marker of intestinal inﬂammation in cystic ﬁbrosis (CF) patients.
Methods: Thirty-six stable CF patients (age range 13 to 28 years) without overt
gastrointestinal symptoms and 36 age-matched controls were included in the study.
Plasma citrulline levels were measured by ion-exchange high performance liquid
chromatography. Possible relationship of plasma citrulline levels to the nutritional
status of CF patients was also studied.
Results: Plasma citrulline levels did not statistically differ between CF patients
and age-matched controls (38±7 mmol/L and 39±11mmol/L respectively). Nine
patients were malnourished while 27 patients had normal nutrition. Comparison
of plasma citrulline levels between patients with malnutrition and patients with
normal nutrition did not reveal any differences, either (37±7 and 38±8 mmol/L
respectively).
Conclusions: Plasma citrulline did not appear to be a sensitive marker of intestinal
inﬂammation in stable CF patients. The presence of malnutrition did not affect
plasma citrulline levels and our results agree with previous reports in conditions
other than cystic ﬁbrosis.
